My best-performing share the past two years are by far Fortnox. At the same time, the Fortnox share does not attract much attention in forums and elsewhere investors discuss their investments. Probably because the news flow is low. There is a report, then three months later another. During these three months, the only thing that had happened is that Fortnox earns more money, acquire more customers and have a better marginal. That is why I think of Fortnox as a silent winner. Continue reading
Well, so far April has been a busy month. I have sold my house and will move closer to Copenhagen, so for the moment I have devoted a lot my time to cardboard box packing. Nevertheless, a number of significant events have occurred in relation to my portfolio. Hence this post with short news on different companies. First, I have sold my Photocat shares. Next, the shares issue in Phase Holographic is complete – while A1M Pharma announced that they wanted an issue, too. Then it seems troublesome for IVISYS to attract money from their warrants. Norwegian Visma have prolonged the acceptance period for their offer on Fortnox shares. Finally, Dignitana have reported a number of hospitals and clinics using their cooling cap – without much effect on the share price. Continue reading
March have been a month of extremes in the portfolio. Overall, the portfolio performance is up by 5% on average, but in one end, Fortnox went up 45% and Nexam 40 %, while on the other hand Dignitana went down 13.5 % and G5 Entertainment 11%. In all, the portfolio has not yet recovered from the onslaught in January and February and is still down 15 %, while the broad OMX-SPI is down 4.3 %. Continue reading
This week’s main news from my portfolio concerns Fortnox. But besides this a number of things are happening. In this short news post I will visit Recyctec, Nexam, Heliospectra, cast an eye on a noteworthy share price development concerning CybAero, and finally I give links to three resent investor meetings.
The main news this week was of course the takeover bid on Fortnox Monday 14th. Norwegian Visma made an offer of +32%, the general meeting was postponed until May, and investors are right now waiting for more information on the bid. During the week rumours of competing bids – nice if the price is up! – resistance from the main owner, pros and cons, etc. was a topic in different forums. And again I wonder: for many of the participants in these debates it seems more like football fans discussing their favourite team, than investors trying to figure out how they make the best investment. Continue reading
The news from Fortnox this morning came as a surprise as it was announced that Visma, a competitor of Fortnox, has made bid to take-over Fortnox. Visma offers 24 SEK each share and the offer runs the first three weeks of April. The price offered for Fortnox is 1.4 billion SEK. Visma is a Norwegian company founded in 1996, active in the Nordic countries, Netherlands, and Baltic States and have grown via numerus acquisitions since (10 in 2014 alone). Continue reading
February 9th Fortnox published the year-end report and the 10th the CEO, Sara Arildsson, left the company. The official reason for her departure was differences in views on ‘management and strategic direction’. In many respects, the report was good, but from Wednesday morning (10th) to Thursday afternoon, the share dropped 8.9 %. In the same timespan, OMXSPI went up, so the departure of Sara Arildsson, recruited in October 2014, was perceived by the market as negative. Continue reading
February is the months for year-end reports. The year circle of many companies follows the calendar, and throughout February, they are published – with a few in January and a few in March.
For growth shares at an early stage of their development the year-end reports is not the main driver of the share price. For lager companies guidance given in reports often have an impact on the share price. The share price development of growth shares are governed more by non-financial press releases: a CE-marking, an initial order, a FDA-approval etc. than by financial results.
Of my portfolio, I expect the share price of Nexam will gain by the report – with Fortnox, G5 Entertainment, Heliospectra, and Recyctec as probable benefactors. Continue reading
December was a green month – in more than one sense. The weather was warm and my lawn seemed to grow in both November and December, but more interesting the predominant colour in my portfolio performance for December is green.
In this post, I will evaluate the portfolio performance in December (and in 2015) and give a few comments of what to expect in 2016. The performance first. Continue reading
In general, November was a fine month. Shares went up and my portfolio performance was good with 9 out of 13 shares rising. Of the 13 shares, 6 were up more that 15%, 4 between app. 0 and 10 % and only 3 fell . On a year-to-date-basis, the portfolio is up 60 %. Continue reading
In the past week, a number of press releases have occurred regarding the companies in my portfolio of growth shares. I collect these news in a portfolio short news post. Readers of my blog knows that the prime driver of share prices in growth shares lies in the press releases – and not in changed guidance as with large cap shares. Therefor the press releases are worth reading an commenting upon. This week there are news from AroCell, Heliospectra, Fortnox, CybAero, and G5 Entertainment. Continue reading